Journal
FRONTIERS IN PHARMACOLOGY
Volume 12, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fphar.2021.628690
Keywords
chemotherapy; targeted therapy; endocrine therapy; drug resistance; PI3K
Categories
Funding
- National Key Research and Development Program of China [2020YFA0112300, 2018YFC2000400]
- National Natural Science Foundation of China [81830087, U1602221, 31771516, 81360393, 81760480, 81960479, 82060542]
- project of Innovative Research Team of Yunnan Province [2019HC005]
- top young talents of ten thousand talents plan in Yunnan Province [YNWRQNBJ-2019-275]
- Yunnan Province Science and Technology Department-Kunming Medical University Joint Fund for Fundamental Research [2019FE001082]
- general projects of basic research in Yunnan Province [2019FB113]
- Hundred-Talent Program of Kunming Medical University [60118260119]
- Health Science and technology project of Yunnan province [2018NS0052]
- medical discipline leader of Yunnan province [D-2019029]
Ask authors/readers for more resources
Hyperactivation of the PI3K/AKT/mTOR pathway is associated with drug resistance and cancer progression in breast cancer patients. Current research is focusing on developing drugs targeting this pathway to overcome acquired resistance to standard therapies.
Although chemotherapy, targeted therapy and endocrine therapy decrease rate of disease recurrence in most breast cancer patients, many patients exhibit acquired resistance. Hyperactivation of the PI3K/AKT/mTOR pathway is associated with drug resistance and cancer progression. Currently, a number of drugs targeting PI3K/AKT/mTOR are being investigated in clinical trials by combining them with standard therapies to overcome acquired resistance in breast cancer. In this review, we summarize the critical role of the PI3K/AKT/mTOR pathway in drug resistance, the development of PI3K/AKT/mTOR inhibitors, and strategies to overcome acquired resistance to standard therapies in breast cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
